Authors
Latest:
Dr. Nguyen on Primary Analysis of the FORMULA-509 Trial in Prostate CancerPaul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.
Latest:
Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.
Latest:
Metastatic CRPC: Novel Treatment Strategies With Radioligand TherapyKey opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Latest:
Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid TumorsSachdev P. Thomas, MD, discusses the utility of the immunotherapy response score when predicting clinical benefit with pembrolizumab in advanced solid tumors.
Latest:
Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast CancerShanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Latest:
Dr Hwang on the Potential Use of Multicancer Early Detection Tests in Breast Cancer ScreeningShelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.
Latest:
Dr Hannan on the Advantages of Stereotactic Radiation in Primary and Locally Advanced RCCRaquibul Hannan, MD, PhD, discusses the advantages of stereotactic radiation in primary or locally advanced renal cell carcinoma.
Latest:
Research on CAR T Therapy in Earlier Lines of TreatmentAmit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Latest:
Dr Bezerra on the Real-World Efficacy of Brexu-Cel in B-ALLEvandro D. Bezerra, MD, discusses real-world outcomes associated with brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.
Latest:
Dr Abushahin on Biomarker Testing in mCRCLaith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.
Latest:
Extending the Frontiers of Checkpoint Inhibition in Merkel Cell CarcinomaIn the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Latest:
Dr. Ahn on Choosing Between Treatment Options in CLLInhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.
Latest:
Unmet Needs and Future of Lower-Risk MDSThe panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
Latest:
Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid TumorsAurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.
Latest:
Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBCKarim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPCUlka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
Latest:
Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic CancerWen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.
Latest:
Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck CancersDrug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.
Latest:
Practical Advice for Management of Chronic GVHDThe panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.
Latest:
Dr Merchán on the Role of Immunotherapy and TKI Combinations in RCCJaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr Knight on Diagnosing and Managing Brain-Metastatic Prostate AdenocarcinomaJames Knight, MD, discusses a case study of a patient with brain-metastatic prostate adenocarcinoma.
Latest:
Leveraging BTK Inhibitors in Chronic Lymphocytic LeukemiaThe choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.
Latest:
Key Takeaways For Treating Patients Diagnosed With CholangiocarcinomaProvider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Latest:
Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLCDavid Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Latest:
Evolving Treatment Landscape of HER2+ Metastatic Breast CancerClosing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
Latest:
Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast CancerGretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.
